On the origin and significance of serum CA-125 concentrations in 97 patients with endometriosis before, during, and after buserelin acetate, nafarelin, or danazol.

Franssen AM, van der Heijden PF, Thomas CM, Doesburg WH, Willemsen WN, Rolland R

Fertility and sterility1 May 1992Cited by 15 (Europe PMC)

PMID1533376DOI10.1016/s0015-0282(16)55011-0PepBankPUB-01533376

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanObservational studyMechanism
In women with endometriosis, nafarelin and buserelin reduced CA-125 to the same extent in a retrospective analysis.
In plain wordsIn women with endometriosis, nafarelin and buserelin were linked to similar CA-125 reductions in a retrospective analysis.
Peptide
Nafarelin
Outcome
Direction not reportedCA-125 reduction versus buserelin
Study
n = 82
Comparator
Buserelin acetate
Outcome group
Reproductive biomarkers · Reproductive and sexual health
Studied dose
400 micrograms/d · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
All three treatment regimens reduced CA-125 concentrations to the same extent; cessation of therapy was followed by restoration to pretreatment concentrations.
3 context sentences(design, population, supporting numbers)
Summary · context
Retrospective.
Summary · context
Ninety-seven women with endometriosis who participated in two trials: (1) open-label study on buserelin acetate (n = 51) and (2) comparative, placebo-controlled study on nafarelin (n = 31) versus danazol (n = 15) (2:1 ratio).
Summary · context
(1) Buserelin acetate 900 micrograms/d intranasally (IN); (2) nafarelin 400 micrograms/d IN versus danazol 400 mg/d orally during 6 months.
Report a problemFND-0153337603
02HumanObservational studyMechanism
In women with endometriosis, nafarelin and danazol reduced CA-125 to the same extent in a retrospective analysis.
In plain wordsIn women with endometriosis, nafarelin and danazol were linked to similar CA-125 reductions in a retrospective analysis.
Peptide
Nafarelin
Outcome
Direction not reportedCA-125 reduction versus danazol
Study
n = 46
Comparator
Danazol
Outcome group
Reproductive biomarkers · Reproductive and sexual health
Studied dose
400 micrograms/d · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
All three treatment regimens reduced CA-125 concentrations to the same extent; cessation of therapy was followed by restoration to pretreatment concentrations.
3 context sentences(design, population, supporting numbers)
Summary · context
Retrospective.
Summary · context
Ninety-seven women with endometriosis who participated in two trials: (1) open-label study on buserelin acetate (n = 51) and (2) comparative, placebo-controlled study on nafarelin (n = 31) versus danazol (n = 15) (2:1 ratio).
Summary · context
(1) Buserelin acetate 900 micrograms/d intranasally (IN); (2) nafarelin 400 micrograms/d IN versus danazol 400 mg/d orally during 6 months.
Report a problemFND-0153337604
03HumanObservational studyMechanism
In women with endometriosis, CA-125 decreased during nafarelin treatment, as it did with buserelin and danazol.
In plain wordsIn women with endometriosis, CA-125 decreased during nafarelin treatment, as it did with buserelin and danazol.
Peptide
Nafarelin
Outcome
DecreaseCA-125 during treatment
Study
n = 31
Comparator
Pretreatment
Outcome group
Reproductive biomarkers · Reproductive and sexual health
Studied dose
400 micrograms/d · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
All three treatment regimens reduced CA-125 concentrations to the same extent; cessation of therapy was followed by restoration to pretreatment concentrations.
3 context sentences(design, population, supporting numbers)
Summary · context
Retrospective.
Summary · context
Ninety-seven women with endometriosis who participated in two trials: (1) open-label study on buserelin acetate (n = 51) and (2) comparative, placebo-controlled study on nafarelin (n = 31) versus danazol (n = 15) (2:1 ratio).
Summary · context
(1) Buserelin acetate 900 micrograms/d intranasally (IN); (2) nafarelin 400 micrograms/d IN versus danazol 400 mg/d orally during 6 months.
Report a problemFND-0153337601
04HumanObservational studyMechanism
In women with endometriosis, CA-125 returned to pretreatment concentrations after nafarelin cessation, as with the other regimens.
In plain wordsIn women with endometriosis, CA-125 returned to pretreatment levels after nafarelin cessation, as with the other regimens.
Peptide
Nafarelin
Outcome
IncreaseCA-125 after cessation
Study
n = 31
Comparator
During treatment
Outcome group
Reproductive biomarkers · Reproductive and sexual health
Studied dose
400 micrograms/d · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
All three treatment regimens reduced CA-125 concentrations to the same extent; cessation of therapy was followed by restoration to pretreatment concentrations.
3 context sentences(design, population, supporting numbers)
Summary · context
Retrospective.
Summary · context
Ninety-seven women with endometriosis who participated in two trials: (1) open-label study on buserelin acetate (n = 51) and (2) comparative, placebo-controlled study on nafarelin (n = 31) versus danazol (n = 15) (2:1 ratio).
Summary · context
(1) Buserelin acetate 900 micrograms/d intranasally (IN); (2) nafarelin 400 micrograms/d IN versus danazol 400 mg/d orally during 6 months.
Report a problemFND-0153337602

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.